FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.
What happened
In August 2025, FDA reviewed the website https://www.master-pharmaceuticals.com and observed that it offered compounded semaglutide and tirzepatide drug products. FDA found website claims labeling the products “Semaglutide (Ozempic/Wegovy)” and “Tirzepatide (Mounjaro/Zepbound).” FDA said these claims imply the compounded products are the same as FDA-approved products when they are not, so the products are misbranded.
What FDA found
Website claims compared compounded semaglutide and tirzepatide to FDA-approved brand products, making the labeling false or misleading.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising or promotion for the compounded drugs was false or misleading.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receipt or delivery of misbranded drugs in interstate commerce is prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to take immediate action, including ceasing the misleading language, and to respond in writing within 15 working days to OCQC in CDER describing corrective steps, how it will prevent recurrence, and related documents. If it cannot complete the matter in that time, it must explain the delay and give a timeframe.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and their marketing partners
- brands or consumers buying compounded GLP-1 drugs online
This is a summary. Read the original letter on fda.gov.